Comparative Pharmacology
Head-to-head clinical analysis: INAPSINE versus PERSERIS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INAPSINE versus PERSERIS KIT.
INAPSINE vs PERSERIS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
None Documented
None Documented
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Category C
Category C
Antipsychotic
Antipsychotic